|3Jul 29, 9:59 PM ET

ElevateBio, LLC 3

3 · Allovir, Inc. · Filed Jul 29, 2020

Insider Transaction Report

Form 3
Period: 2020-07-29
Holdings
  • Series A-2 Convertible Preferred Stock

    Common Stock (13,420,970 underlying)
Footnotes (2)
  • [F1]Each share of convertible preferred stock is convertible on a one-for-1.49021 basis into Common Stock at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The convertible preferred stock has no expiration date.
  • [F2]Shares held by ElevateBio LLC ("ElevateBio"). David Hallal, Vikas Sinha, Morana Jovan-Embiricos and Ansbert Gadicke are directors of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. Such persons disclaim beneficial ownership of all shares held by ElevateBio except to the extent of their pecuniary interest therein, if any.

Documents

2 files